

Christine Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6954579/publications.pdf>

Version: 2024-02-01

23
papers

1,117
citations

932766

10
h-index

887659

17
g-index

23
all docs

23
docs citations

23
times ranked

1726
citing authors

#	ARTICLE	IF	CITATIONS
1	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2013, 14, 1055-1066.	5.1	710
2	Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. <i>Blood</i> , 2018, 132, 2546-2554.	0.6	110
3	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. <i>Blood</i> , 2018, 131, 855-863.	0.6	105
4	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	3.3	54
5	Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 2668-2673.	0.6	27
6	Secondary primary malignancies during the lenalidomide+dexamethasone regimen in relapsed/refractory multiple myeloma patients. <i>Cancer Medicine</i> , 2017, 6, 3-11.	1.3	24
7	Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. <i>EJHaem</i> , 2021, 2, 56-65.	0.4	15
8	Selinexor in Combination with Bortezomib and Dexamethasone (SdB) Demonstrates Significant Activity in Patients with Refractory Multiple Myeloma (MM) Including Proteasome-Inhibitor Refractory Patients: Results of the Phase I Stomp Trial. <i>Blood</i> , 2016, 128, 977-977.	0.6	15
9	Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 387-394.	0.2	11
10	A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 4509-4509.	0.6	10
11	Tolerability of Velcade (Bortezomib) subcutaneous administration using a maximum volume of 3 mL per injection site. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 285-292.	0.5	9
12	Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 225-234.	0.2	7
13	Computerized cognitive training in post-treatment hematological cancer survivors: a feasibility study. <i>Pilot and Feasibility Studies</i> , 2021, 7, 36.	0.5	6
14	Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 3330-3330.	0.6	6
15	Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma: A Retrospective Review of a Single-center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e195-e203.	0.2	4
16	Pattern of First Relapse in Multiple Myeloma (MM) Patients (Pts) after a Cybord Induction Regimen and Autologous Stem Cell Transplantation (ASCT): Impact of Maintenance Therapy in the Real-World Setting. <i>Blood</i> , 2016, 128, 2137-2137.	0.6	3
17	Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Heavy/light, C Chain (HLC) Ratio Assessments. <i>Blood</i> , 2016, 128, 4632-4632.	0.6	1
18	Outcomes of patients with relapsed low-grade lymphoma retreated with rituximab are similar to rituximab naïve patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 2576-2579.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 23-30.	1.4	0
20	Myeloma Canada Research Network (MCRN)-001 Trial Utilizing Bortezomib (btz)-Based Induction, Enhanced Conditioning with IV Busulfan + Melphalan (BuMel) and Lenalidomide (len) Maintenance in Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplant (ASCT): A National Canadian Study Evaluating Achievement of Minimal Residual Disease (MRD) Negativity and Involved Serum Heavy Chain (HLC) Normalization. <i>Blood</i> , 2015, 126, 1982-1982.	0.6	0
21	Single Centre Experience in Treating Newly Diagnosed t(4;14) Multiple Myeloma with and without Planned Front-Line Autologous Stem Cell Transplant. <i>Blood</i> , 2016, 128, 3457-3457.	0.6	0
22	Is Prior Rituximab Exposure Associated with a Difference in Outcomes in Relapsed Low-Grade Lymphomas Retreated with Rituximab in Comparison to Rituximab Naïve Patients?. <i>Blood</i> , 2016, 128, 1795-1795.	0.6	0
23	Cost Analysis of Stored Autologous Peripheral Blood Stem Cells for a Second Autologous Transplantation in Multiple Myeloma Patients: A Markov Model. <i>Blood</i> , 2016, 128, 1184-1184.	0.6	0